NT5E and glioblastoma: As a pre-clinical example of a therapeutic correlation between TIGIT and CD73 in GBM, our study demonstrates the benefit of these two pathways as therapeutic co-targets in GBM, and the superior potential of usurping their activities in contrast to pharmacological blockade alone.